Viral Vector-Based Vaccines: Current and Future Perspectives
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 4322
Special Issue Editor
Interests: virus-host interactions; molecular virology; innate immune signaling pathways; molecular biology; microbiology; cell biology; immunology; oncolytic virotherapy and immunotherapy; cancer biology; development of therapeutic proteins
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Viral vectors are one of the most successful platforms for vaccines and gene therapy. Many types of viruses are developed as vaccine and gene therapy vectors for the past several decades. Viral vector-based vaccines can be either non-replicating or replicating. Currently, against the COVID-19 pandemic, many viral vector-based vaccines are under development, and few are authorized to use.
The viral vector-based vaccines provide several advantages, including triggering a robust immune response that involves the production of antibodies by B cells and cellular immune response by T cells. However, challenges remain with many viral vectors as vaccines, such as having pre-existing immunity and risk of pathogenesis from replicating competent vectors. Future efforts to design and optimize in different aspects will eventually result in the best use of these vector-based vaccines.
This special issue of vaccines will focus on the current research, application, development, and challenges ahead with viral vector-based vaccines in the context of antigen expression, immunogenicity, delivery, protection, safety, and manufacturing. Articles on viral vectors that are also used as gene therapy are also welcome in this issue.
Prof. Masmudur M. Rahman
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Keywords: viral vectors
- viral infections
- vaccines
- immune response
- vaccine platforms
- vaccine development
- vaccine production
- vaccine delivery
- vaccine safety
- antigen design
- virus-like particles
- VLPs
- COVID-19
- SARS-CoV-2
- antibodies
- cellular immunity
- clinical trials
